Lisinopril vs Losartan Side Effects: Which Blood Pressure Drug Is Right for You?

What Is the Core Difference Between Lisinopril and Losartan?

Both drugs block the renin-angiotensin-aldosterone system (RAAS), but at different points. Lisinopril stops angiotensin-converting enzyme (ACE) from making angiotensin II. Losartan blocks the receptor that angiotensin II would bind to. That single mechanistic difference explains almost every side-effect gap between them.

Because lisinopril blocks ACE, bradykinin accumulates. Bradykinin is a vasodilating peptide that cannot be broken down when ACE is inhibited. In women, estrogen amplifies bradykinin receptor sensitivity, which is one reason the persistent dry cough that lisinopril causes is reported roughly twice as often in women as in men. Losartan does not raise bradykinin levels, so it does not cause this cough.

This is not a minor quality-of-life footnote. Cough is the most common reason women discontinue ACE inhibitor therapy, and switching to an ARB like losartan resolves it in the vast majority of cases.

The Side-Effect Profile, Compared Head-to-Head

No randomized trial has compared lisinopril directly against losartan with side effects as the primary endpoint. What follows is a synthesis across trial data, pharmacovigilance databases, and sex-stratified observational studies.

Dry Cough

This is the defining tolerability difference. ACE inhibitor-induced cough occurs in 10 to 20% of patients overall, but women experience it at rates approaching 40% in some series. The cough is dry, persistent, worse at night, and does not resolve with dose reduction. The only fix is switching drug class.

Losartan does not cause this cough. If you are already on lisinopril and experiencing a nagging dry cough that your doctor has not yet connected to your medication, this is the most likely explanation.

Angioedema

Angioedema is a potentially life-threatening swelling of the lips, tongue, throat, or gut. Lisinopril carries a 3 to 5 times higher risk of angioedema than ARBs. Black women carry the highest population risk. A history of prior ACE inhibitor-induced angioedema is an absolute contraindication to restarting any ACE inhibitor. Losartan is generally considered safe in this setting, though a small cross-reactivity rate exists.

Blood Pressure Efficacy

Head-to-head, both drugs lower systolic blood pressure by roughly 10 to 15 mmHg at standard doses (lisinopril 10 to 40 mg daily; losartan 50 to 100 mg daily). The ALLHAT trial (JAMA 2002) found lisinopril equivalent to chlorthalidone for coronary heart disease outcomes but noted a modestly worse stroke profile in the subgroup that included more Black participants. The LIFE trial (Lancet 2002) demonstrated a 13% reduction in the composite primary endpoint of cardiovascular death, stroke, and myocardial infarction with losartan versus atenolol in patients with left ventricular hypertrophy, establishing losartan's cardioprotective credential independent of blood pressure reduction alone.

Potassium and Kidney Function

Both drugs raise potassium. This matters in women with chronic kidney disease, adrenal insufficiency, or those using potassium-sparing diuretics. The effect is roughly equivalent between classes at therapeutic doses, though individual responses vary. Women with PCOS who are already on spironolactone (a potassium-sparing drug used for androgen excess and hormonal acne) face additive hyperkalemia risk if either drug is added.

Dizziness and Blood Pressure Drops

Losartan may cause slightly more dizziness with the first dose, particularly if you are volume-depleted from a diuretic or from inadequate hydration. This is dose-dependent. Starting at 25 mg and titrating up reduces first-dose hypotension risk.

Metabolic and Lipid Effects

Neither drug significantly alters lipids. Losartan has a well-documented uric acid-lowering effect, unique among ARBs, because it blocks renal urate reabsorption. For women with hyperuricemia, gout, or metabolic syndrome, this is a clinically useful differentiator.

How Your Hormonal Status Changes the Picture

Reproductive Years (Ages 18 to 40)

If you are premenopausal and sexually active, contraception is not optional with either drug. Both are teratogens. See the dedicated pregnancy section below.

Estrogen at premenopausal levels increases bradykinin sensitivity, meaning the cough risk with lisinopril is at its highest during your reproductive years. If you are placed on lisinopril and develop a cough within weeks to months of starting, speak with your prescriber about switching to losartan rather than adding a cough suppressant.

Women with PCOS who have hypertension or early microalbuminuria often use either drug for renal protection. Losartan may be preferable in this group if spironolactone is already part of the regimen, because the combination of spironolactone plus an ACE inhibitor carries a higher hyperkalemia risk than spironolactone plus an ARB, though the absolute risk difference is small and both combinations require monitoring.

Perimenopause (Typically Ages 40 to 55)

Blood pressure frequently rises during perimenopause. Estrogen's vasodilatory effects wane, arterial stiffness increases, and sodium retention becomes more common. Hypertension prevalence in women surpasses that in men after age 65, and the trajectory begins in the perimenopausal transition.

Both drugs are appropriate choices in this window. Losartan's uric acid benefit becomes more relevant as metabolic risk accumulates during perimenopause. If you have left ventricular hypertrophy detected on an echocardiogram, the LIFE trial data favors losartan over older drug classes.

Vasomotor symptoms (hot flashes, night sweats) are not caused or significantly worsened by either drug. A small subset of women report flushing with losartan's first-dose hypotensive effect, but this is transient and distinct from menopause-related vasomotor symptoms.

Postmenopause

After menopause, cardiovascular risk rises sharply. Both drugs have strong outcome data in older women, though most major trials enrolled more men than women. The ALLHAT trial did enroll a substantial proportion of women (approximately 47% of participants), making it one of the more sex-representative antihypertensive trials, though its sex-stratified analyses were not its primary focus.

Renal function declines with age. Both drugs are renoprotective in diabetic nephropathy, but both require dose adjustment or discontinuation if estimated GFR falls below 30 mL/min. Annual monitoring of creatinine and potassium is standard practice.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Both lisinopril and losartan are contraindicated throughout pregnancy. This is not a theoretical concern. It is a hard clinical stop.

Pregnancy Risk

ACE inhibitors and ARBs cause fetal renal dysgenesis, oligohydramnios, skull hypoplasia, limb contractures, and death when exposure occurs during the second or third trimester. First-trimester exposure is also now considered harmful based on more recent epidemiological data, overturning earlier guidance that suggested only the second and third trimesters carried meaningful risk.

The FDA previously classified these drugs as Category C in the first trimester and Category D from the second trimester onward, but current labeling carries a unified contraindication throughout pregnancy.

If you discover you are pregnant while taking either drug, contact your prescriber the same day. You will be switched to a pregnancy-safe antihypertensive such as labetalol, nifedipine, or methyldopa.

Contraception Requirement

Any woman of reproductive age prescribed lisinopril or losartan should be using reliable contraception. This means methods with failure rates below 1% per year with typical use: IUDs (hormonal or copper), implants, or sterilization. Oral contraceptive pills add an independent blood pressure effect and may not be the best choice for women already on antihypertensives. Discuss the interaction with your prescriber.

Lactation

Both drugs have limited data in lactation. Lisinopril is transferred into breast milk in small amounts; human infant safety data are insufficient. Losartan's lactation data are similarly sparse. Most guidelines advise against both during breastfeeding and recommend alternatives such as nifedipine or labetalol if blood pressure control is needed postpartum. If you are planning to breastfeed, raise this with your prescriber before delivery so a transition plan is in place.

Postpartum Considerations

Postpartum hypertension is common and can be severe. Women who had preeclampsia or gestational hypertension need careful blood pressure monitoring for at least 6 weeks after delivery. Restarting RAAS-blocking therapy in a non-breastfeeding woman is appropriate once she has confirmed she is not pregnant again and is using reliable contraception.

Who This Is Right For, and Who Should Think Twice

Lisinopril May Be the Better Choice If:

• You have diabetic nephropathy with proteinuria (both classes work, but ACE inhibitors have older, larger trial datasets in this specific setting)
• Your insurance formulary makes lisinopril substantially cheaper (it is available as a generic at very low cost)
• You do not have a history of cough or angioedema with ACE inhibitors
• You are not Black (the angioedema risk differential is most pronounced in Black women)

Losartan May Be the Better Choice If:

• You developed a dry cough on lisinopril or any other ACE inhibitor
• You have a personal or family history of angioedema
• You are Black (lower angioedema risk, and ARBs perform similarly to ACE inhibitors in this population)
• You have hyperuricemia or gout (the uric acid-lowering effect is unique to losartan among ARBs)
• You have left ventricular hypertrophy (the LIFE trial supports a favorable cardiovascular outcome beyond blood pressure lowering)
• You are perimenopausal or postmenopausal with metabolic syndrome

Neither Drug Is Appropriate If:

• You are pregnant or planning pregnancy in the near term
• You are breastfeeding (without a clear discussion with your prescriber and a documented risk-benefit decision)
• Your potassium is already elevated above 5.5 mEq/L without optimization
• You have a history of bilateral renal artery stenosis

Monitoring: What to Expect After Starting Either Drug

The following monitoring framework is specific to women's physiology and accounts for the hormonal and reproductive factors that standard cardiology protocols often do not address.

At 2 weeks: Check creatinine, potassium, and blood pressure. Women who are perimenopausal and estrogen-deficient may respond more briskly to RAAS blockade because their baseline sodium retention is higher.

At 3 months: Assess for ACE inhibitor cough. If present on lisinopril, switch rather than wait. Cough does not resolve with time or dose reduction.

At 6 months: Recheck renal function. Women with autoimmune conditions (lupus nephritis, scleroderma renal crisis) on immunosuppressants need closer monitoring because renal function can shift quickly.

Annually: Full metabolic panel including potassium, creatinine, and GFR. If you are postmenopausal and your GFR is declining, discuss with your nephrologist whether RAAS blockade remains appropriate.

At every visit: Pregnancy status and contraception. This should be a standard part of any visit for a woman of reproductive age on either drug. It is not always asked. Ask it yourself if your prescriber does not.

The Evidence Gap for Women: What We Do Not Yet Know

Women were underrepresented in the large antihypertensive outcome trials. The ALLHAT trial (JAMA 2002) enrolled approximately 47% women but was not powered for sex-specific subgroup analysis. The LIFE trial (Lancet 2002) enrolled approximately 54% women, which is notable, but again the primary analysis was not sex-stratified.

This means several clinically important questions remain unanswered by direct trial data:

• Does the bradykinin-cough mechanism differ across menstrual cycle phases in premenopausal women?
• Does hormone therapy (estrogen-containing HRT) during perimenopause modify the efficacy or tolerability of either drug?
• What is the optimal RAAS-blocking strategy for women with PCOS who have early-onset hypertension before age 40?

The honest answer is that current prescribing for women is largely extrapolated from trials that enrolled mostly men or from mixed-sex trials not designed to detect sex-specific differences. When your prescriber tells you the drugs work the same in women, they are probably right in terms of average blood pressure reduction. The side-effect burden, particularly cough and angioedema, is not the same.

Practical Switching: Can You Go From Lisinopril to Losartan?

Yes. Switching is safe and straightforward. You do not taper lisinopril; you stop it and start losartan the next day. A typical starting dose when switching for cough is losartan 50 mg daily, titrated to 100 mg daily if blood pressure remains above target.

Expect a brief period of adjustment. Blood pressure may fluctuate slightly in the first 1 to 2 weeks. Check your blood pressure at home daily for the first two weeks after switching and report readings above 160/100 mmHg to your prescriber.

The cough from lisinopril typically resolves within 1 to 4 weeks of stopping the ACE inhibitor. If your cough persists beyond 8 weeks after switching, an alternative cause (postnasal drip, asthma, GERD) should be investigated.

A Note on Cost and Access

Generic lisinopril is available for as little as $4, $10 per month at major pharmacy chains. Generic losartan is similarly affordable, typically $10, $25 per month without insurance. Both are on the $4 generic lists at most large pharmacy chains in the United States. Neither drug requires specialty pharmacy access, prior authorization from most insurers for the standard hypertension indication, or step therapy through another drug class first.

If cost is a concern, both drugs are accessible. The choice between them should be made on tolerability, your individual risk profile, and your reproductive status. It should not default to the cheaper option if you are a woman with risk factors for ACE inhibitor-related side effects.